Lupus erythematosus with leflunomide: Induction or reactivation?

51Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background: Leflunomide is a new oral disease modifying antirheumatic drug with a good safety profile. Case report: The first case of lupus erythematosus in a 58 year old white woman after administration of leflunomide for primary Sjögren's syndrome is reported. The relationship between induced lupus and leflunomide was confirmed by the resolution of the skin rash when the drug was stopped and its recurrence when it was reintroduced following a dose-response effect. Discussion: Peripheral blood cells from this patient, from 15 patients with rheumatoid arthritis, and from healthy controls were used in a bioassay, which suggested that leflunomide affected the Th1/Th2 balance. Such a side effect might be related, in part, to the anti-tumour necrosis factor α activity of leflunomide.

Cite

CITATION STYLE

APA

Gensburger, D., Kawashima, M., Marotte, H., Kanitakis, J., & Miossec, P. (2005). Lupus erythematosus with leflunomide: Induction or reactivation? Annals of the Rheumatic Diseases, 64(1), 153–155. https://doi.org/10.1136/ard.2003.019323

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free